KORU Medical Systems to Present Two Abstracts at the Immunoglobulin National Society 2023 National Conference
October 05 2023 - 7:05AM
Business Wire
KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or
the "Company"), a leading medical technology company focused on
the development, manufacturing, and commercialization of innovative
and easy-to-use specialty subcutaneous infusion solutions that
improve quality of life for patients, is pleased to announce its
participation in the Immunoglobulin National Society (“IGNS”) 2023
National Conference, taking place in Denver, Colorado from October
5th to 8th. KORU Medical will present two abstracts during the
conference, furthering its commitment to advancing research and
development in the field of immunodeficiency therapies.
The first abstract, titled "Optimizing Infusion Time in Patients
with Primary Immunodeficiency Disease Using Home-Based Subcutaneous
Immunoglobulin Infusion Therapy," explores the innovative
approaches and techniques developed by KORU Medical to enhance the
infusion experience for patients with primary immunodeficiency
diseases. By streamlining and optimizing infusion times, KORU
Medical aims to improve treatment compliance while maintaining the
highest standards of patient care.
The second abstract, "Factors Contributing to Patient Preference
for Home-Based Subcutaneous Immunoglobulin Therapy," delves into
the patient perspective and investigates the various factors that
contribute to patients' preference for home-based subcutaneous
immunoglobulin therapy. Understanding patient preferences is
crucial in designing patient-centered treatment strategies, and
KORU Medical is committed to delivering solutions that prioritize
patients' comfort, convenience, and overall well-being.
"We are thrilled to have two abstracts accepted for presentation
at the IGNS’ 12th National Conference," said Brent Rutland, Vice
President, Medical Affairs at KORU Medical. "At KORU Medical, we
firmly believe in making a positive impact on patients' lives, and
these abstracts reflect our dedication to advancing the field of
large volume subcutaneous drug delivery. By optimizing the time and
efforts patients with immune deficiencies spend infusing their
life-improving therapies, we aim to enhance their quality of life
and ensure they receive the best possible care."
The posters featuring the abstracts will be presented on
Saturday, October 7th, providing an opportunity for conference
attendees to gain valuable insights into KORU Medical's research
and development efforts. KORU Medical representatives will also be
available throughout the conference to engage in discussions, share
expertise, and explore potential collaborations with healthcare
professionals and researchers.
About KORU Medical Systems
KORU Medical Systems develops, manufactures, and commercializes
innovative and easy-to-use subcutaneous drug delivery systems that
improve quality of life for patients around the world. The FREEDOM™
Infusion System currently includes the FREEDOM60® and FreedomEdge®
Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo
Subcutaneous Safety Needle Sets™. These devices are used for
infusions administered in the home and alternate care settings. For
more information, please visit www.korumedical.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
that involve risks and uncertainties. All statements that are not
historical fact are forward-looking statements and can be
identified by words such as "will" and "aim". Actual results may
differ materially from these statements due to potential risks and
uncertainties such as those included under the captions "Risk
Factors" in our Annual Report on Form 10-K for the year ended
December 31, 2022 and our Quarterly Report on Form 10-Q for the
quarter ended June 30, 2023, which are on file with the SEC and
available on our website at www.korumedical.com/investors and on
the SEC website at www.sec.gov. All information provided in this
release and in the attachments is as of October 5, 2023. Undue
reliance should not be placed on the forward-looking statements in
this press release, which are based on information available to us
on the date hereof. We undertake no duty to update this information
unless required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231005334972/en/
Investor Contact: Greg Chodaczek 347-620-7010
investor@korumedical.com
KORU Medical Systems (NASDAQ:KRMD)
Historical Stock Chart
From Oct 2024 to Nov 2024
KORU Medical Systems (NASDAQ:KRMD)
Historical Stock Chart
From Nov 2023 to Nov 2024